LearnGlossaryMarketStocksSuperinvestorsSign in

GANX

Gain Therapeutics, Inc.

Healthcare · $72M market cap

Verdict

We can't put a fair value on GANX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-34.4% a year✗
Sales growth24.1% a year✓
Free cash flow growth—?
Return on invested capital-73.4%✗

Follow GANX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds GANX. Who we track

David Einhorn

Greenlight Capital · as of Q4 2023

$1.9M

588,410 shares

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works